Tarsus Pharmaceuticals (TARS) Insider Yarno Sells 2,954 Shares
On June 12, 2026, Wendy Yarno sold 2,954 shares of TARS.
Reviewed by automated data checks against the source filing. How we make and check alerts
Wendy Yarno sold 2,954 shares of Tarsus Pharmaceuticals, Inc. ($TARS) on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $TARS is up 2.6% after 1 week, down 4.3% after 1 month and up 9.9% to date (from the $61.95 close on Jun 12, 2026).
TARS
Tarsus Pharmaceuticals, Inc.
Key Points
- Wendy Yarno sold 2,954 shares of TARS on June 12, 2026, with the stock trading at $61.85.
- TARS has strong institutional backing, with major funds like Deep Track Capital and Janus Henderson Group increasing their stakes.
- Analysts remain bullish on TARS, with firms like HC Wainwright & Co. and Oppenheimer maintaining 'buy' ratings and high price targets.
Get $TARS trade alerts by text
We text you when insiders, Congress or big funds trade $TARS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Tarsus Pharmaceuticals, Inc. alert may contain errors. Disclosures
Wendy Yarno sold 2,954 shares of TARS on June 12, 2026. The transaction was not part of a planned trading program. TARS shares were trading at $61.85 at the time of the sale.
Other Institutional Activity in TARS
Several major institutional investors have shown interest in TARS. Deep Track Capital, LP increased its holdings by 595,966 shares, bringing its total to 3.6 million shares valued at roughly $252.54 million. Janus Henderson Group PLC also grew its position, adding 310,638 shares to reach a total of 2.24 million shares worth about $157.22 million. Meanwhile, BlackRock, Inc. reduced its stake by 237,945 shares, ending with 3.55 million shares valued at approximately $249.22 million. Morgan Stanley trimmed its holdings by 96,470 shares, maintaining 1.94 million shares worth around $136.39 million.
Tarsus Pharmaceuticals, Inc. Stock Down 20.8%
TARS shares are currently trading at $61.85. The company has caught the attention of several institutional investors, indicating strong market interest. Analysts also seem optimistic, with multiple firms reiterating or maintaining favorable ratings.
Analysts Set New Price Targets
On May 4, 2026, HC Wainwright & Co. reiterated its 'buy' rating for TARS, setting a price target of $88.0. Earlier in the year, on February 25, 2026, Oppenheimer maintained its 'buy' rating with a target of $105.0, and Guggenheim kept its 'buy' rating with a $90.0 target. Barclays initiated coverage with a 'buy' rating and a $100.0 price target on December 9, 2025.
About TARS
TARS operates in the pharmaceutical sector, focusing on developing and commercializing innovative therapies. The company aims to address unmet medical needs through its advanced drug development programs. Headquartered in the United States, TARS strives to bring new treatments to market that improve patient outcomes.
Bottom Line
Wendy Yarno's recent sale of TARS shares comes amid strong institutional interest and positive analyst sentiment. While insider sales can occur for various reasons, TARS continues to garner support from major funds and analysts. Investors should remember that insider transactions are just one piece of the larger puzzle, and 13F filings reflect past positions.
Related Filing Alerts
Source: Wendy Yarno's Form 4 filing on $TARS (Jun 12, 2026). Find the original filing: TARS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts